PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Clinical trials for PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) explained in plain language.
Never miss a new study
Get alerted when new PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) trials appear
Sign up with your email to follow new studies for PANCREATIC DUCTAL ADENOCARCINOMA (PDAC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New catheter technique aims to boost chemo power against tough pancreatic cancer
Disease control Not yet recruitingThis early-phase trial tests a new method of delivering chemotherapy directly to pancreatic tumors through a catheter. The goal is to see if this approach is safe and can help shrink tumors more effectively before surgery, potentially leading to better outcomes for patients with …
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1, PHASE2 • Sponsor: University of Vermont • Aim: Disease control
Last updated May 26, 2026 04:21 UTC
-
New hope for Hard-to-Treat cancers: drug targets RAS mutations
Disease control Not yet recruitingThis study tests an experimental drug called BPI-572270 in 120 adults with advanced solid tumors (lung, colorectal, or pancreatic cancer) that have specific RAS gene mutations. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Participan…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1, PHASE2 • Sponsor: Betta Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 04:18 UTC
-
New hope for advanced gut cancers? drug combo trial launches
Disease control Not yet recruitingThis study tests a new drug called SSGJ-706 combined with standard treatments for people with advanced cancers of the stomach, colon, pancreas, or esophagus that cannot be removed by surgery. About 300 adults aged 18-75 will take part to see if the combination is safe and helps s…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE2 • Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD. • Aim: Disease control
Last updated May 26, 2026 04:15 UTC
-
New drug aims to shrink tough pancreatic tumors in phase 2 trial
Disease control Not yet recruitingThis study tests a drug called HLX43 in 100 people with advanced pancreatic cancer that has not responded to other treatments. The drug is designed to target and attack cancer cells while limiting harm to healthy cells. The main goals are to see if tumors shrink and how long that…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE2 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated May 26, 2026 04:13 UTC
-
Hand grip strength may reveal hidden clues in pancreatic cancer
Knowledge-focused Not yet recruitingThis study looks at whether measuring hand grip strength in adults with pancreatic cancer can give doctors useful information about how the disease and treatment are progressing. About 50 participants will squeeze a handheld device and answer questionnaires during regular clinic …
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: NA • Sponsor: British Columbia Cancer Agency • Aim: Knowledge-focused
Last updated May 26, 2026 04:23 UTC
-
Bile drain before pancreatic surgery: help or hindrance?
Knowledge-focused Not yet recruitingThis study looks at whether draining bile before surgery (called pre-operative biliary drainage) changes tumor features or survival in people with pancreatic cancer. Researchers will review medical records of 90 patients who had their pancreatic tumor removed over 8 years. The go…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Sponsor: East Lancashire Hospitals NHS Trust • Aim: Knowledge-focused
Last updated May 26, 2026 04:22 UTC
-
Scientists hunt for clues to personalize pancreatic cancer therapy
Knowledge-focused Not yet recruitingThis study aims to find biological markers in blood and stool that can predict how well patients with advanced pancreatic cancer will respond to treatment. Researchers will analyze samples from 140 participants to develop a personalized treatment plan. The goal is to improve outc…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Sponsor: Chang Gung Memorial Hospital • Aim: Knowledge-focused
Last updated May 18, 2026 12:11 UTC